Debasish Sundi, MD
Academic Title: Assistant Professor in the College of Medicine
Research Program: Cancer Biology
I am a urologist specializing in urologic oncology. I obtained my medical training at Northwestern University in Chicago and completed my surgical residency in urology at Johns Hopkins University in Baltimore. Subsequently, I completed a fellowship in urologic oncology at the University of Texas MD Anderson Cancer Center. Treatment for urologic cancers can include multiple treatment choices, and I enjoy getting to know my patients and their priorities to determine the best care plans for each individual patient. As a member of the Cancer Biology Program at the OSUCCC – James, my research focuses on exploring the functions of immune suppressive cells in the bladder cancer tumor microenvironment (in particular, myeloid derived suppressor cells) and identifying and blocking MDSC-specific signaling pathways. In so doin, my aim is to overcome therapeutic resistance to immune checkpoint blockade, which is a pressing clinical issue in bladder cancer. I am also exploring the use of beta-catenin inhibitors to modulate the tumor immune microenvironment and studying determinants of bladder cancer chemosensitivity. In addition to performing research, which has been published in numerous peer-reviewed journals, I also serve as an editor for BMC Cancer and a reviewer for European Urology, Urologic Oncology, Journal of Urology and PLoS ONE. While I was at Johns Hopkins, I received the Frank L. Coulson, Jr., Award for Clinical Excellence, and my research in prostate cancer was recognized by ASCO in 2013 as one of the Clinical Cancer Advances of the year. While I was at MD Anderson, I received the Conquer Cancer Foundation of ASCO Merit Award and the William L. Pippin Endowed Fellowship for my work in bladder cancer research. The OSUCCC – James is an incredible place. A direct benefit of the cutting-edge research and technology here is that I can offer my patients state-of-the-art treatment strategies and surgical options that maximize safety and precision. I am proud to be a member of The James, and to be part of the process that lifts oncology care to such heights is a true honor.
- Bladder Cancer
- Kidney Cancers
- Testicular Cancers
- Urology
- Prostate Cancers
- Adrenal Gland Cancers
- Urethral Cancers
- Hematuria
- Minimally Invasive Surgical Procedures
- Robotics
Internship - Surgery (General Surgery)
- Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD
Residency - Urology
- Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD
Medical School
- Northwestern University Feinberg School of Medicine
420 E Superior St, Chicago, IL
Fellowship - Urologic Oncology
- University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX
- Johns Hopkins Hospital
Academic Office:
Tzagournis Medical Research Fa 0690A
420 W 12th Ave
Columbus, Ohio 43210-2208Email:
sundi.1@osu.edu- October 2, 2024
A Slow March Toward Eliminating Transfusion in Uro-Oncology.
Dason S, Sundi D, Sood A
JAMA Surg
May 1, 2024Bladder Cancer, Version 3.2024.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA
J Natl Compr Canc Netw
April 26, 2024Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
Purdue MP, Dutta D, Machiela MJ, Gorman BR, Winter T, Okuhara D, Cleland S, Ferreiro-Iglesias A, Scheet P, Liu A, Wu C, Antwi SO, Larkin J, Zequi SC, Sun M, Hikino K, Hajiran A, Lawson KA, Cárcano F, Blanchet O, Shuch B, Nepple KG, Margue G, Sundi D, Diver WR, Folgueira MAAK, van Bokhoven A, Neffa F, Brown KM, Hofmann JN, Rhee J, Yeager M, Cole NR, Hicks BD, Manning MR, Hutchinson AA, Rothman N, Huang WY, Linehan WM, Lori A, Ferragu M, Zidane-Marinnes M, Serrano SV, Magnabosco WJ, BioBank Japan Project , Vilas A, Decia R, Carusso F, Graham LS, Anderson K, Bilen MA, Arciero C, Pellegrin I, Ricard S, FinnGen , Scelo G, Banks RE, Vasudev NS, Soomro N, Stewart GD, Adeyoju A, Bromage S, Hrouda D, Gibbons N, Patel P, Sullivan M, Protheroe A, Nugent FI, Fournier MJ, Zhang X, Martin LJ, Komisarenko M, Eisen T, Cunningham SA, Connolly DC, Uzzo RG, Zaridze D, Mukeria A, Holcatova I, Hornakova A, Foretova L, Janout V, Mates D, Jinga V, Rascu S, Mijuskovic M, Savic S, Milosavljevic S, Gaborieau V, Abedi-Ardekani B, McKay J, Johansson M, Phouthavongsy L, Hayman L, Li J, Lungu I, Bezerra SM, Souza AG, Sares CTG, Reis RB, Gallucci FP, Cordeiro MD, Pomerantz M, Lee GM, Freedman ML, Jeong A, Greenberg SE, Sanchez A, Thompson RH, Sharma V, Thiel DD, Ball CT, Abreu D, Lam ET, Nahas WC, Master VA, Patel AV, Bernhard JC, Freedman ND, Bigot P, Reis RM, Colli LM, Finelli A, Manley BJ, Terao C, Choueiri TK, Carraro DM, Houlston R, Eckel-Passow JE, Abbosh PH, Ganna A, Brennan P, Gu J, Chanock SJ
Nat Genet
February 10, 2024Roles of Androgen Receptor Signaling in Urothelial Carcinoma.
Sundi D, Collier KA, Yang Y, Diaz DA, Pohar KS, Singer EA, Gupta S, Carson WE, Clinton SK, Li Z, Messing EM
Cancers (Basel)
January 12, 2024A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines.
Patel DM, Mateen R, Qaddour N, Carrillo A, Verschraegen C, Yang Y, Li Z, Sundi D, Mortazavi A, Collier KA
Cancers (Basel)
January 5, 2024Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.
Verma S, Swain D, Kushwaha PP, Brahmbhatt S, Gupta K, Sundi D, Gupta S
Cancers (Basel)
January 1, 2024Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer.
McConkey DJ, Baumann BC, Cooper Greenberg S, DeGraff DJ, Delacroix SE, Efstathiou JA, Foster J, Groshen S, Kadel EE, Khani F, Kim WY, Lerner SP, Levin T, Liao JC, Milowsky MI, Meeks JJ, Miyamoto DT, Mouw KW, Pietzak EJ, Solit DB, Sundi D, Tawab-Amiri A, West PJ, Wobker SE, Wyatt AW, Apolo AB, Black PC
Bladder Cancer
December 27, 2023PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA
Eur Urol Oncol
April 13, 2023Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics.
Chandra M, Li R, Parwani A, Carson WE, Pohar K, Sundi D
Urol Oncol
August 19, 2022Sex-biased adaptive immune regulation in cancer development and therapy.
Schafer JM, Xiao T, Kwon H, Collier K, Chang Y, Abdel-Hafiz H, Bolyard C, Chung D, Yang Y, Sundi D, Ma Q, Theodorescu D, Li X, Li Z
iScience
April 14, 2022Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer.
Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z
Sci Immunol
March 15, 2021Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
Wilkins LJ, Tosoian JJ, Reichard CA, Sundi D, Ranasinghe W, Alam R, Schwen Z, Reddy C, Allaf M, Davis JW, Chapin BF, Ross AE, Klein EA, Nyame YA
Cancer
March 10, 2021Robotic Radical Cystectomy, Pelvic Lymph Node Dissection, and Intracorporeal Ileal Conduit Urinary Diversion.
Stillings SA, Sundi D
J Vis Exp
January 9, 2021Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times.
McCaw ZR, Odisho AY, Chaparala H, Yin M, Cloyd J, Svatek RS, Carson WE, Lee CT, Sundi D
Urol Oncol
November 10, 2020Surgical management of high-risk, localized prostate cancer.
Wilkins LJ, Tosoian JJ, Sundi D, Ross AE, Grimberg D, Klein EA, Chapin BF, Nyame YA
Nat Rev Urol
April 7, 2020Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Allaf ME, Davis JW, Chapin BF
J Urol
March 3, 2020Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM
Eur Urol
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Sundi has reported no relationships with companies or entities.